IceCure Medical Reports Q3 2025 Results
Ticker: ICCM · Form: 6-K · Filed: Nov 19, 2025 · CIK: 1584371
Sentiment: neutral
Topics: financial-results, 6-K, quarterly-report
Related Tickers: ICUR
TL;DR
ICUR dropped Q3 results on 11/19/25 - check the 6-K for details.
AI Summary
IceCure Medical Ltd. filed a Form 6-K on November 19, 2025, to report its financial and operational results for the nine months ended September 30, 2025. The filing includes a press release detailing these results, which is attached as Exhibit 99.1.
Why It Matters
This filing provides investors with an update on IceCure Medical's financial performance and operational activities for the first three quarters of 2025.
Risk Assessment
Risk Level: low — This is a routine filing providing financial results, not indicating new significant risks.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report
- November 19, 2025 (date) — Date of the filing and press release
- September 30, 2025 (date) — End date for the reported financial period
- Exhibit 99.1 (document) — Attached press release with financial results
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the financial and operational results of IceCure Medical Ltd. for the nine months ended September 30, 2025, through an attached press release.
When was the press release detailing the financial results issued?
The press release was issued on November 19, 2025.
What period do the reported financial results cover?
The reported financial results cover the nine months ended September 30, 2025.
What is the Commission File Number for IceCure Medical Ltd.?
The Commission File Number for IceCure Medical Ltd. is 001-40753.
Where is IceCure Medical Ltd. headquartered?
IceCure Medical Ltd. is headquartered in Caesarea, Israel.
Filing Stats: 310 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-11-19 09:05:07
Filing Documents
- ea0266219-6k_icecure.htm (6-K) — 12KB
- ea026621901ex99-1_icecure.htm (EX-99.1) — 97KB
- 0001213900-25-112380.txt ( ) — 111KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: November 19, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3